Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. (Q33926114)

30 July 2017

title

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. (English)

1 reference

30 July 2017

main subject

chronic myeloid leukemia

0 references

3

Hagop Kantarjian

1 reference

30 July 2017

4

Jorge Cortes

1 reference

30 July 2017

Yiming Chen

1

1 reference

30 July 2017

Haijun Wang

series ordinal

2

1 reference

30 July 2017

publication date

5 December 2012

1 reference

30 July 2017

1 reference

30 July 2017

volume

54

1 reference

30 July 2017

issue

7

1 reference

30 July 2017

page(s)

1411-1417

1 reference

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

5 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Chronic myeloid leukaemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

5 July 2018

Chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Disappearance of pH1-Positive Cells in Four Patients with Chronic Granulocytic Leukemia after Chemotherapy, Irradiation and Marrow Transplantation from an Identical Twin

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia

5 July 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Survival advantage from imatinib compared with the combination interferon- plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials

29 October 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.745525

Occupational benzene exposure and the risk of chronic myeloid leukemia: A meta-analysis of cohort studies incorporating study quality dimensions

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5525971

Chronic myelogenous leukemia

29 October 2018

1 reference

12 December 2020

Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha

1 reference

12 December 2020

Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia

1 reference

12 December 2020

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease

1 reference

12 December 2020

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

12 December 2020

Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

12 December 2020

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

12 December 2020

Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia

1 reference

12 December 2020

Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients

1 reference

12 December 2020

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

12 December 2020

Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation

1 reference

12 December 2020

10.3109/10428194.2012.745525

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference